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Abstract
Objective To investigate frequency and risk factors for prevalent,
incident, and persistent carcinogenic human papillomavirus (HPV) in
young women before the introduction of immunisation against HPV types
16 and 18 for schoolgirls.
Design Cohort study
Setting 20 London universities and further education colleges.
Participants 2185 sexually active female students, mean age 21 years
(range 16-27), 38% from ethnic minorities, who took part in the POPI
(prevention of pelvic infection) chlamydia screening trial in 2004-08 and
who provided duplicate, self taken vaginal swabs and completed
questionnaires at baseline. At follow-up, a median of 16 months later,
821 women (38%) returned repeat vaginal swabs by post. In 2009-10,
stored samples were tested for HPV.
Results Samples from 404/2185 (18.5% (95% CI 16.9% to 20.2%)) of
the cohort were positive for carcinogenic HPV at baseline, including
15.0% (327) positive for non-vaccine carcinogenic genotypes. Reporting
two or more sexual partners in the previous year and concurrent
Chlamydia trachomatis or bacterial vaginosis were independent risk
factors for prevalent vaginal HPV infection. Infection with one or more
new HPV types was found in 17.7% (145/821) of follow-up samples,
giving an estimated annual incidence of carcinogenic HPV infection of
12.9% (95% CI 11.0% to 15.0%). Incident infection was more common
in women reporting two or more partners in the previous year, aged<20,
of black ethnicity, or with C trachomatis vaginosis at baseline. Multiple
partners was the only independent risk factor for incident infection
(adjusted relative risk 1.99 (95% CI 1.46 to 2.72)). Of 143 women with
baseline carcinogenic HPV infection, 20 (14% (8.3% to 19.7%) had
infection with the same carcinogenic HPV type(s) detected after 12-28
months. Of these women, 13 (65%) had redetected infection with HPV
16 or 18, and nine (45%) with non-vaccine carcinogenic HPV genotypes.
Conclusion In the first UK cohort study of carcinogenic HPV in young
women in the community, multiple sexual partners was an independent
predictor of both prevalent and incident infection. Infection with
non-vaccine carcinogenic genotypes was common. Although current
HPV vaccines offer partial cross protection against some non-vaccine
carcinogenic HPV types, immunised women will still need cervical
screening.
Introduction
Each year around 500 000 women are diagnosed with invasive
cervical cancer worldwide and 250 000 women die from it,
mainly in developing countries.1 Persistent infection with a
carcinogenic human papillomavirus (HPV) is a prerequisite for
cervical cancer,2 and around 20% of women with one year
persistence of HPV infection in the cervix will develop cervical
intraepithelial neoplasia or cervical cancer in the next five years.3
HPV genotypes 16 and 18 are responsible for around 70% of
cervical cancers, with the remaining 30% caused by other
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carcinogenic HPV types. HPV16 is the most carcinogenic type
in terms of numbers of cases of cervical intraepithelial neoplasia
or cervical cancer.4 5 Low risk genotypes 6 and 11 cause most
cases of genital warts. Although HPV infections are the most
common viral sexually transmitted infection, most infections
are transient and asymptomatic, with about 70% of new
infections resolving within a year.2 6 7
Immunisation against HPV types 16 and 18 protects against
cervical intraepithelial neoplasia.8 9 Since 2008, the UK-wide
HPV immunisation programme has been vaccinating adolescent
schoolgirls against carcinogenic HPV16 and HPV18, but there
is a dearth of UK baseline data on HPV infection in women
from non-healthcare settings, especially those in some ethnic
minorities who may have a higher risk of cervical cancer but
lower uptake of immunisation and cervical screening.10 11 These
data are essential to monitor the impact of the vaccination
programme and to guide the ongoing introduction of HPV
testing.
We used stored vaginal samples from women who took part in
the POPI (prevention of pelvic infection) chlamydia screening
trial,12 which was before the introduction of the immunisation
programme, to investigate the frequency and risk factors for
prevalent, incident, and persistent carcinogenic HPV infection
in young women in the community.
Methods
Study population
The design of the POPI trial has been described elsewhere.12
Briefly, during 2004-06, 2529 female students were recruited
from 20 London universities and further education colleges.
Students were eligible to take part if they were aged ≤27 years,
female, sexually experienced, not pregnant, and had not been
tested forChlamydia trachomatis infection in the previous three
months. They were asked to complete a questionnaire and to
provide two self-taken vaginal swabs.13 One swab was used for
the chlamydia screening trial. The other was rolled over a glass
slide for bacterial vaginosis analysis, placed in Aptima transport
medium (Gen Probe) and stored at –80°C. Twelve months after
recruitment, 94% of participants were followed up by
questionnaire or medical record search.12 Those who agreed to
repeat vaginal swabs were sent two swabs for return by post.
One swab was tested for C trachomatis immediately and the
result fed back to the participant, the other was stored. For the
current study we analysed stored baseline samples (including a
subset previously described14) and the follow-up samples,
enabling repeat testing for HPV.
Laboratory testing for HPV
In 2009-10 the stored specimens from the baseline and follow-up
vaginal swabs were tested for HPV by the Health Protection
Agency. HPV testing was conducted anonymously; results were
not fed back to participants. Samples were initially screened for
HPV infection with the Digene Hybrid Capture 2 assay, which
includes probes for high risk and low carcinogenic risk. The
specimens that tested positive were subsequently genotyped
using the Roche Linear Array HPV Genotyping assay.14 15 This
test can detect 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68,
69, 70, 71, 72, 73 (MM9), 81, 82 (MM4), 83 (MM7), 84 (MM8),
IS39, and CP6108) and includes a β-globin probe to check for
sample integrity to reduce the risk of false negatives. Of 323
samples that tested positive with the Hybrid Capture 2 assay
but negative with the Linear Array assay, β-globin was not
detected in two baseline samples and these were excluded. In
line with the 2009 classification by the International Agency
Research on Cancer,16 we defined 13 “probably carcinogenic”
genotypes as high risk carcinogenic HPV types (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 68).
We defined incident HPV infection as a positive swab at
follow-up in women who were negative for the same
carcinogenic HPV genotype at baseline. Infection with the same
carcinogenic HPV genotype in both baseline and follow-up
samples was classified as persistence or redetection of HPV
infection, recognising that some of these cases could have been
due to clearance and subsequent re-infection with the sameHPV
genotype.8
Sample size
The sample size for the study was constrained by the 2529
women recruited to the POPI trial.12We assumed the prevalence
of HPV16 was 5%.4 Given that 28% of the cohort was of black
ethnicity,12 this sample size would allow detection of a difference
in the prevalence of HPV16 of 7% in black women compared
with 4% in the remainder with 80% power and 5% significance.
Statistical analysis
We investigated demographic and behavioural risk factors often
associated with sexually transmitted infections: young age, black
ethnicity, smoking, multiple sexual partners, sexual debut at
age <16 years, and use of oral contraception or condoms.6 13 17 18
As sexually transmitted infections often coexist, we also looked
at concurrentChlamydia trachomatis,Mycoplasma genitalium,
Neisseria gonorrhoeae, or bacterial vaginosis.
We used data on the baseline samples for analysis of predictors
of prevalent carcinogenic HPV infection and used data for
women who returned follow-up samples to analyse predictors
of incident infection and persistent or redetected infection. We
examined the relation between possible risk factors and prevalent
carcinogenic HPV infection at baseline, and incident or
persistent or redetected HPV at follow-up, using binomial
regression with a log link in Stata, version 10. Results are
presented as relative risks. For prevalent and incident infections,
multivariate analyses were conducted which included all
variables found to be statistically significant in the univariate
analyses, plus variables that were non-significant but have
previously been shown to be related to HPV infection (age <20,
age <16 at sexual debut, and smoking6 17 18). As the number of
persistent or redetected infections was small, we performed only
univariate analyses for the eight risk factors found to be
associated with prevalent or incident infection.
We estimated the annual incidence of HPV infection by dividing
the number of incident cases by the total person years of
follow-up from date of recruitment to date of providing the
repeat vaginal sample (range 11-32months).We then expressed
the rate per 100 person years as the percentage annual incidence.
Calculation of the true incidence for new infections would have
required information on the date of infection, which was not
available. We calculated rates of persistence or redetection for
each carcinogenic genotype for HPV positive women at baseline
who returned repeat samples by dividing the number of women
with the same HPV genotype at both baseline and follow-up by
the number with that genotype at baseline.
Results
Follow-up
Of the 2529 women recruited to the trial, 2185 (86%) provided
duplicate vaginal samples at baseline that were suitable for HPV
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analysis (see figure⇓). Of these women, 821 (38%) returned
repeat postal samples after 11-32 months (median 16 months).
Compared with non-responders, the womenwho returned repeat
samples were slightly older and less likely to be of black
ethnicity, or to smoke, use condoms, or have bacterial vaginosis
at baseline (see appendix table 1 on bmj.com).
Prevalence of carcinogenic HPV infection at
baseline
Of the 2185 women, 404 (18.5% (95% CI 16.9% to 20.2%))
were positive for carcinogenic HPV at baseline (table 1⇓).
HPV16 was the most common carcinogenic HPV infection
(prevalence 5.4% (4.5% to 6.4%)). However, 327 women (15%)
had infection with at least one non-vaccine carcinogenic HPV
type and 144 (7%) had multiple carcinogenic HPV infections.
Of the 51 women infected with HPV6 and nine women infected
with HPV11, only two (3.3%) gave a history of genital warts.
Predictors of prevalent carcinogenic HPV
infection
Carcinogenic HPV infection wasmore common amongwomen
of black ethnicity, those who smoked, those reporting two or
more sexual partners in the previous 12 months, those who
reported using condoms (no data available on frequency of use),
and those with concurrent C trachomatis, M genitalium, N
gonorrhoeae, or bacterial vaginosis (table 2⇓). Multivariate
analysis showed that having multiple partners in the previous
12 months and co-infection with C trachomatis or concurrent
bacterial vaginosis were independent predictors of carcinogenic
HPV infection.
Incidence of carcinogenic HPV infection
Of the 821womenwho provided follow-up samples, 145 (17.7%
(15.1% to 20.4%)) were infected with one or more new HPV
genotypes (table 1⇓ and figure⇓). Taking into account the timing
of the follow-up sample (median 16 months after recruitment),
the estimated annual incidence was 12.9% (11.0% to 15.0%)
for any carcinogenic HPV infection and 9.8% (8.1% to 11.7%)
for non-vaccine genotypes. Predictors of incident infection were
age <20 years, black ethnicity, reporting two or more sexual
partners in the previous 12 months, reported condom use, and
C trachomatis infection at baseline (table 3⇓). Having two or
more partners was the only independent predictor of incident
carcinogenic HPV infection.
Persistence or redetection of carcinogenic
HPV infection of specific type
Of the 821 women returning follow-up samples, 143 (17.4%)
had one or more carcinogenic HPV infections at baseline, and
20/821 (2.4% (1.4% to 3.5%)) had infection with at least one
of the same genotypes redetected after 12-28 months. Thus one
in seven women (20/143, 14.0% (8.3% to 19.7%)) with baseline
infection had either not cleared their infection or been reinfected
with the same genotype (table 1⇓). Of these 20women, 13 (65%)
had persistent or redetected HPV16 or HPV18 infection and
nine (45%) had a non-vaccine HPV type. Persistence or
redetection of specific carcinogenic HPV types was not
significantly associated with sexual behaviour, demography,
smoking, or co-infection but the numbers were small (appendix
table 2 on bmj.com).
Vaccine HPV types (HPV16 and HPV18)
Rates of prevalent, incident, and persistent or redetected
infection with HPV16 or HPV18, or both, are shown in table
4⇓. Around one in five women with HPV16 or HPV18 at
baseline had persistent or redetected infection after a median of
16 months follow-up. Infections with vaccine HPV types were
more likely to persist or be redetected than infections with
non-vaccine HPV types: 21% (13/63) versus 9% (9/104).
Discussion
Principal findings
In this community based cohort of multiethnic female students,
the prevalence and annual incidence of carcinogenic HPVwere
18% and 13%, and reporting multiple sexual partners in the
previous 12 months was an independent predictor of both
prevalent and incident infection. Among women who returned
follow-up samples after a median of 16 months, 14% of those
with baseline infection (that is, 2% overall) had persistent or
redetected HPV infection with the same carcinogenic genotype.
Nearly half of these women had persistent or redetected infection
with non-vaccine HPV genotypes.
Strengths and weaknesses
This is the first UK cohort study of carcinogenic HPV infection
in women recruited at educational institutions rather than from
healthcare facilities. It provides useful baseline data on HPV
infection in England before the introduction of HPV
immunisation. It enabled some investigation of the association
of carcinogenic HPV infection with concurrent C trachomatis,
Mgenitalium,N gonorrhoeae, or bacterial vaginosis. More than
a third of the women returning follow-up samples were
teenagers, many from ethnicminorities. Although black ethnicity
was associated with prevalent and incident carcinogenic HPV
infection in univariate analysis, it was not a significant
independent risk factor for infection. Finally the study provides
new information on demographics, smoking, and sexual
behaviour related to carcinogenic HPV infection in England.
The main weakness is the study was not population based. This
limits generalisability of our findings. However, these data may
be the best currently available from a community based cohort
of young women in the UK. A recent Scottish population based
survey requesting 5500 unscreened young women aged over 21
to take vaginal swabs and return them by post for HPV testing
had a 13% response rate.19
We may have underestimated the annual incidence of
carcinogenic HPV infection for three reasons. Only 38% of the
cohort returned follow-up postal samples so data on incidence
(and on redetection or persistence) are based on a self selected,
probably lower risk group as they were older and less likely to
smoke or to be from an ethnic minority. Secondly, we used
length of follow-up as a proxy for time to infection, which will
have overestimated the time at risk and underestimated the
incidence. Thirdly, as median duration of HPV infection is
around eight months,6 we probably missed some women who
acquired and cleared a new HPV infection in the median 16
month interval between testing at baseline and at follow-up
swab. Also we cannot be sure that some cases of apparent HPV
persistence were not clearance and reinfection with the same
genotype.
The sample size was restricted to 2185 women who took part
in the POPI trial and 821 who participated in follow-up, limiting
the power to identify and adjust for risk factors. Small numbers
of women with persistent or redetected infection meant that risk
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factors for this could not be robustly evaluated. However, other
cohort studies were of similar size.4 6 17 Although self collected
vaginal swabs are reliable for detection of HPV,20 HPV types
in the vagina may differ from those in the cervix. In the samples
that screened positive for HPV infection but were negative in
the HPV genotyping assay there were some indications of
reduced sensitivity (notwithstanding the high rate of β-globin
positivity indicating sample integrity), probably due to the long
storage time.14 Finally, findings may not be applicable to
different populations such as those in developing countries or
women attending genitourinary, family planning, or hospital
clinics.
Comparison with other studies
Themost common carcinogenic HPV genotypes we found were
16, 18, 51, 52, and 59, which is similar to findings from other
UK studies4 14 15 21 and multinational incidence studies in men.22
As in reports from clinic based studies, risk factors for prevalent
and incident carcinogenic HPV infection were similar to those
for other sexually transmitted infections: multiple sexual
partners,6 17 18 young age,6 ethnic minority background,6 and
co-infection.17 The unexpected association of prevalent HPV
with reported condom use may be because condoms are more
likely to be used, but not consistently, by those at higher risk.
Others have also found reported condom use was not protective
against HPV infection,18 although consistent condom use may
be.23
However it is persistent carcinogenic HPV infection which
explains virtually all cases of cervical cancer.1 Ho and
colleagues’ finding that 28% (7/25) of women with HPV16 at
baseline had persistent HPV16 infection for 24 months6 is
similar to our redetection rate of HPV16 of 24% (11/46); and,
as in our study, persistent infection for six months was not
associated with smoking, but numbers were small.6 Another
report from a selected population of women with equivocal or
mildly abnormal cytology also suggested that six month
persistence of HPV infection was not associated with smoking
except possibly in women smoking more than 20 cigarettes
daily.24
Implications of study
Many women diagnosed with carcinogenic HPV infection of
the cervix are worried about the risk of developing cervical
cancer. Although they can be reassured that most new infections
clear spontaneously, we found that one in seven women with
carcinogenic HPV infection at baseline had persistent or
redetected infection for up to 28 months, nearly half of them
with carcinogenic genotypes not covered by current HPV
vaccines. In September 2012 the UK-wide HPV vaccination
programmewill be switching from the bivalent vaccine targeting
HPV types 16 and 18 to the quadrivalent vaccine, which also
targets HPV types 6 and 11.25Both vaccines provide some cross
protection against cervical intraepithelial neoplasia associated
with carcinogenic HPV types 31, 33, 45, 52, and 58,9 26 27 though
cross protection seems stronger with the bivalent vaccine.9
However, since around 20-30% of cervical cancers in the UK
andmany persistent infections are due to non-vaccine genotypes,
choice of vaccine may need to be re-evaluated when a second
generation broad spectrum HPV vaccine including these
additional five carcinogenic genotypes becomes available.
Meanwhile, both vaccinated and unvaccinated women should
be informed of the importance of continued cervical cytology
and/or HPV testing.1 26
New English guidelines recommend that cervical samples from
women with borderline or mild dyskaryosis are analysed for
carcinogenic HPV infection. Women who test positive will be
referred for colposcopy. Those who are negative will be returned
to routine recall. But policy makers need more evidence on
which women are most at risk of carcinogenic HPV, which HPV
genotypes should be included in assays used for cervical
screening, and appropriate intervals between tests. Our findings
may be used to informmodelling of the possible impact of HPV
vaccination in the UK, including changes in the epidemiology
of non-vaccine carcinogenic HPV types, and the development
of cervical screening strategies.28 5
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Tables
Table 1| Prevalence, incidence, and persistence or redetection of genital infection with carcinogenic HPV genotypes in 2185 female students,
of whom 821 (38%) returned follow-up samples after a median of 16 months
Persistence or redetection (same HPV
type at follow-up)*Incidence (new infection at follow-up)Prevalence (infected at baseline)
Carcinogenic
HPV
genotype
% of 20 women
infected with
each genotype
No (%) of women
with specific HPV
type at baseline
% of 145 women
infected with
each genotype
No (%) of women
tested†
% of 404 women
infected with
each genotype
No (%) infected of
2185 women tested
10020/143 (14)‡100145/821 (17.7)100404 (18.5)Any
5511/46 (24)31.045/775 (5.8)29.2118 (5.4)16
102/20 (10)8.312/801 (1.5)12.450 (2.3)18
102/11 (18)11.016/810 (2.0)9.940 (1.8)31
00/82.13/813 (0.4)5.221 (1.0)33
00/53.45/816 (0.6)5.020 (0.9)35
00/124.87/809 (0.9)7.430 (1.4)39
153/6 (50)6.29/815 (1.1)7.229 (1.3)45
00/3420.029/787 (3.7)24.097 (4.4)51
51/16 (6)15.222/805 (2.7)12.952 (2.4)52
00/107.611/811 (1.4)6.928 (1.3)56
00/98.312/812 (1.5)10.141 (1.9)58
102/16 (13)15.923/805 (2.9)13.153 (2.4)59
51/4 (25)3.45/817 (0.6)4.016 (0.7)68
6513/63 (21)‡34.550/758 (6.6)39.4159 (7.3)16,18, or both
204/40 (10)‡29.743/821 (5.2)35.6144 (6.6)≥2 genotypes
459/104 (9)‡75.9110/821 (13.4)80.9327 (15.0)Non-vaccine
genotypes§
Percentages for individual genotypes sum to >100% because women could be infected with >1 genotype.
*Detection of same carcinogenic HPV genotype in baseline and follow-up samples.
†Denominators exclude women with the same HPV genotype at baseline.
‡Infected with any of the same genotypes at follow-up.
§Defined as not HPV types 16 or 18.
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Table 2| Risk factors for prevalent carcinogenic HPV infection (n=404) in 2185 women at baseline
Relative risk (95% CI) of HPV infection
No (%) of women with HPV infection by presence of
characteristicNo (%) of women
with characteristicCharacteristic Adjusted*CrudeWithout characteristicWith characteristic
0.97 (0.81 to1.17)1.12 (0.94 to 1.34)219/1246 (17.6)185/939 (19.7)939/2185 (43)Age <20 years
1.20 (0.98 to1.47)1.28 (1.06 to 1.54)273/1593 (17.1)127/579 (21.9)579/2172 (27)Black ethnicity
1.07 (0.88 to1.30)1.28 (1.07 to 1.54)254/1493 (17.0)149/682 (21.8)682/2175 (31)Smoker
1.87 (1.54 to 2.26)2.09 (1.74 to 2.51)156/1240 (12.6)245/932 (26.3)932/2172 (43)≥2 sexual partners in
previous year
0.97 (0.79 to1.18)1.05 (0.86 to1.27)281/1536 (18.3)117/612 (19.1)612/2148 (28)Age <16 years at first sex
-1.04 (0.87 to 1.24)203/1117 (18.2)197/1046 (18.8)1046/2163 (48)Use of oral contraception
1.11 (0.93 to1.34)1.28 (1.07 to1.53)162/1004 (16.1)239/1160 (20.6)1160/2164 (54)Use of condoms†
1.57 (1.21 to 2.04)2.05 (1.59 to 2.63)359/2056 (17.5)45/126 (35.7)126/2182 (5.8)Chlamydia trachomatis
infection
1.07 (0.71 to1.63)1.54 (1.05 to 2.26)381/2082 (18.3)20/71 (28.2)71/2153 (3.3)Mycoplasma genitalium
infection
1.34 (1.11 to 1.63)1.56 (1.30 to1.88)258/1560 (16.5)133/515 (25.8)515/2075 (25)Bacterial vaginosis
1.11 (0.46 to 2.66)2.71 (1.21 to 6.01)398/2154 (18.5)3/6 (50)6/2160 (0.3)Neisseria gonorrhoeae
infection
*Controlled for all significant variables from the unadjusted analysis and for age <20 and age <16 at first sex.
†No data on frequency of condom use.
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Table 3| Risk factors for incident carcinogenic HPV infection (n=145) in 821 women who provided follow-up samples after a median of 16
months
Relative risk (95% CI) of HPV infection
No (%) of women with incident HPV infection by
presence of characteristicNo (%) of women
with characteristicCharacteristic Adjusted*CrudeWithout characteristicWith characteristic
1.20 (0.89 to 1.63)1.51 (1.13 to 2.03)79/529 (14.9)66/292 (22.6)292/821 (36)Age <20 years†
1.37 (0.96 to1.94)1.44 (1.03 to 2.02)110/672 (16.4)35/148 (23.6)148/820 (18)Black ethnicity
0.98 (0.70 to1.37)1.18 (0.85 to1.62)102/603 (16.9)43/216 (19.9)216/819 (26)Smoker†
1.99 (1.46 to 2.72)2.10 (1.57 to 2.82)66/522 (12.6)79/297 (26.6)297/819 (36)≥2 sexual partners in
previous year‡
1.20 (0.86 to1.65)1.24 (0.91 to1.70)97/584 (16.6)47/228 (20.6)228/812 (28)Age <16 years at first sex
—1.10 (0.81 to1.48)62/371 (16.7)82/448 (18.3)448/819 (55)Use of oral contraception‡
1.25 (0.91 to1.72)1.56 (1.34 to 2.14)49/361 (13.6)93/439 (21.2)439/800 (55)Use of condoms‡
1.06 (0.60 to1.87)1.76 (1.07 to 2.90)133/780 (17.1)12/40 (30.0)40/820 (4.9)Chlamydia trachomatis
infection
—1.32 (0.94 to1.85)105/627 (16.7)36/163 (22.1)163/790 (21)Bacterial vaginosis
—1.49 (0.73 to 3.00)138/784 (17.6)6/23 (26.1)23/807 (2.9)Mycoplasma genitalium
infection
–——143/806 (17.7)0/22/808 (0.25)Neisseria gonorrhoeae
infection
*Controlled for all significant variables from the unadjusted analysis and for age <20 and age <16 at first sex.
†Reported at baseline.
‡Reported at follow-up. No data on frequency of condom use.
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Table 4| Prevalence, incidence, annual incidence, and persistence or redetection of infection with HPV types 16 or 18, or both, in 2185
female students, of whom 821 (38%) returned follow-up samples after a median of 16 months. Values are numbers and percentages (95%
confidence intervals)
Persistence or redetection (same HPV type at follow-up)
Estimated annual
incidence
Incidence (new
infection at follow-up)*
Prevalence (infected
at baseline)HPV genotype
In all women with follow-up
samples*
In women with same HPV type
at baseline†
11/821
1.3% (0.7% to 2.4%)
11/46
24% (12.6% to 38.8%)
4.2% (3.1% to 5.6%)45/775
5.8% (4.3% to 7.7%)
118/2185
5.4% (4.5% to 6.4%)
16
13/821
1.6% (0.8% to 2.7%)
13/63
21% (11.5% to 32.7%)
5.3% (4.0% to 6.9%)50/758
6.6% (4.9% to 8.6%)
159/2185
7.3% (6.2% to 8.4%)
16, 18, or both
*Follow-up 11–32 months (median 16 months) from recruitment.
†Follow-up 12–23 months (median 16 months) from recruitment for HPV16 alone and for HPV16, 18, or both.
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Figure
Flow of participants through the study
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